Literature DB >> 28935649

Melanoma Sequentially Suppresses Different DC Subsets in the Sentinel Lymph Node, Affecting Disease Spread and Recurrence.

Mari F C M van den Hout1,2, Bas D Koster3, Berbel J R Sluijter4, Barbara G Molenkamp4, Rieneke van de Ven3, Alfons J M van den Eertwegh3, Rik J Scheper1, Paul A M van Leeuwen4, M Petrousjka van den Tol4, Tanja D de Gruijl5.   

Abstract

Melanoma exerts immune-suppressive effects to facilitate tumor progression and metastatic spread. We studied these effects on dendritic cell (DC) and T-cell subsets in 36 melanoma sentinel lymph node (SLN) from 28 stage I-III melanoma patients and determined their clinical significance. Four conventional DC subsets, plasmacytoid DCs, and CD4+, CD8+, and regulatory T cells (Tregs), were analyzed by flow cytometry. We correlated these data to clinical parameters and determined their effect on local and distant melanoma recurrence, with a median follow-up of 75 months. In stage I and II melanoma, increased Breslow thickness (i.e., invasion depth of the primary melanoma) was associated with progressive suppression of skin-derived migratory CD1a+ DC subsets. In contrast, LN-resident DC subsets and T cells were only affected once metastasis to the SLN had occurred. In stage III patients, increased CD4:CD8 ratios in concert with the accumulation of Tregs resulted in decreased CD8:Treg ratios. On follow-up, lower frequencies of migratory DC subsets proved related to local melanoma recurrence, whereas reduced maturation of LN-resident DC subsets was associated with distant recurrence and melanoma-specific survival. In conclusion, melanoma-mediated suppression of migratory DC subsets in the SLN precedes local spread, whereas suppression of LN-resident DC subsets follows regional spread and precedes further melanoma dissemination to distant sites. This study offers a rationale to target migratory as well as LN-resident DC subsets for early immunotherapeutic interventions to prevent melanoma recurrence and spread. Cancer Immunol Res; 5(11); 969-77. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2017        PMID: 28935649     DOI: 10.1158/2326-6066.CIR-17-0110

Source DB:  PubMed          Journal:  Cancer Immunol Res        ISSN: 2326-6066            Impact factor:   11.151


  13 in total

Review 1.  Personal Neoantigen Cancer Vaccines: A Road Not Fully Paved.

Authors:  Edward F Fritsch; Ute E Burkhardt; Nir Hacohen; Catherine J Wu
Journal:  Cancer Immunol Res       Date:  2020-12       Impact factor: 11.151

Review 2.  Tumor-draining lymph nodes: At the crossroads of metastasis and immunity.

Authors:  Haley du Bois; Taylor A Heim; Amanda W Lund
Journal:  Sci Immunol       Date:  2021-09-03

Review 3.  Cancer vaccines: Building a bridge over troubled waters.

Authors:  MacLean C Sellars; Catherine J Wu; Edward F Fritsch
Journal:  Cell       Date:  2022-07-13       Impact factor: 66.850

Review 4.  Current challenges for cancer vaccine adjuvant development.

Authors:  William S Bowen; Abhishek K Svrivastava; Lalit Batra; Hampartsoum Barsoumian; Haval Shirwan
Journal:  Expert Rev Vaccines       Date:  2018-02-08       Impact factor: 5.217

Review 5.  Lymph Node Cellular Dynamics in Cancer and HIV: What Can We Learn for the Follicular CD4 (Tfh) Cells?

Authors:  Antigoni Poultsidi; Yiannis Dimopoulos; Ting-Fang He; Triantafyllos Chavakis; Emmanouil Saloustros; Peter P Lee; Constantinos Petrovas
Journal:  Front Immunol       Date:  2018-09-27       Impact factor: 7.561

6.  Selectively hampered activation of lymph node-resident dendritic cells precedes profound T cell suppression and metastatic spread in the breast cancer sentinel lymph node.

Authors:  Kim M van Pul; Ronald J C L M Vuylsteke; Rieneke van de Ven; Elisabeth A Te Velde; Emiel J Th Rutgers; Petrousjka M van den Tol; Hein B A C Stockmann; Tanja D de Gruijl
Journal:  J Immunother Cancer       Date:  2019-05-22       Impact factor: 13.751

Review 7.  Therapy with CD4+CD25+ T regulatory cells - should we be afraid of cancer?

Authors:  Mateusz Gliwiński; Magdalena Piotrowska; Dorota Iwaszkiewicz-Grześ; Zuzanna Urban-Wójciuk; Piotr Trzonkowski
Journal:  Contemp Oncol (Pozn)       Date:  2019-04-05

Review 8.  Unlocking the therapeutic potential of primary tumor-draining lymph nodes.

Authors:  Jossie Rotman; Bas D Koster; Ekaterina S Jordanova; A Marijne Heeren; Tanja D de Gruijl
Journal:  Cancer Immunol Immunother       Date:  2019-04-03       Impact factor: 6.968

Review 9.  Human Plasmacytoid Dendritic Cells and Cutaneous Melanoma.

Authors:  Matilde Monti; Francesca Consoli; Raffaella Vescovi; Mattia Bugatti; William Vermi
Journal:  Cells       Date:  2020-02-11       Impact factor: 6.600

10.  Plasmacytoid Dendritic Cell Impairment in Metastatic Melanoma by Lactic Acidosis.

Authors:  Matilde Monti; Raffaella Vescovi; Francesca Consoli; Davide Farina; Daniele Moratto; Alfredo Berruti; Claudia Specchia; William Vermi
Journal:  Cancers (Basel)       Date:  2020-07-28       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.